News

November 26, 2019

Alpha DaRT™ achieves a 78.6% complete response rate in management of challenging squamous cell carcinoma tumors.


Tel Aviv, Israel, November 26, 2019 – Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a...

September 4, 2019

Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy Alpha DaRT, announced today the appointment of Dr. Robert B. Den, MD, as Chief Medical Officer (CMO). In his new role, and as a prominent expert and accomplished clinician, Dr. Den will lea...

January 31, 2019

Radiation therapy, the use of high-energy particles or waves, such as x-rays, gamma rays, electrons, or protons, has long been used to treat cancer. From as early as the 20th Century, physicians have given regular doses of radiation to greatly improve the patient’s cha...

Cancer is the most devastating chronic disease affecting humankind. More than 1 out of 3 people in the United States will have cancer during their lifetimes, of which 30% of them will die 5 years from diagnosis [i].  As people live longer, the number of new cancer case...

Please reload

Categories
Please reload

Sign up
Featured Posts

Breakthrough Cancer Therapy Developer, Alpha Tau, Awarded ISO 13485 Certificate for Quality Management of Medical Devices

April 11, 2019

1/5
Please reload

Archive
Please reload

Follow Us
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon

CONTACT US

Are you looking to participate in clinical trials?

Take our self-assessment test to find potentially suitable studies.

For other inquiries, please visit our contact page.